FDA approves Aptiom (Sunovion) to treat Epilepsy
The FDA on 8 November 2013 has approved Aptiom (eslicarbazepine acetate) from Sunovion as an add-on medication to treat seizures associated with Epilepsy. Aptiom is approved for the treatment of partial seizures, the most common type of seizure seen in people with epilepsy. Seizures can cause a wide range of symptoms, including repetitive limb movements, unusual behavior and generalized convulsions with loss of consciousness. Seizures can have serious consequences, including injury and death.
Eslicarbazapine acetate was approved in Europe on 21 April 2009 as Zebinix and is marketed there by Eisai.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.